e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novartis AG Common Stock
(NY:
NVS
)
169.22
+3.71 (+2.24%)
Streaming Delayed Price
Updated: 2:56 PM EST, Feb 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,354,583
Open
169.11
Bid (Size)
169.21 (200)
Ask (Size)
169.23 (300)
Prev. Close
165.51
Today's Range
168.85 - 170.46
52wk Range
97.72 - 168.02
Shares Outstanding
N/A
Dividend Yield
2.36%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
February 26, 2026
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...
Via
MarketMinute
Topics
Economy
Intellectual Property
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
↗
February 25, 2026
Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.
Via
The Motley Fool
Topics
Stocks
Performance
YTD
+22.1%
+22.1%
1 Month
+11.2%
+11.2%
3 Month
+29.8%
+29.8%
6 Month
+33.8%
+33.8%
1 Year
+56.7%
+56.7%
More News
Read More
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
February 25, 2026
Via
MarketMinute
Topics
Intellectual Property
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals
↗
February 19, 2026
Via
Chartmill
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
↗
February 24, 2026
Via
The Motley Fool
Topics
Intellectual Property
Retirement
Arvinas (ARVN) Q4 2025 Earnings Call Transcript
↗
February 24, 2026
Via
The Motley Fool
Topics
Earnings
Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short
↗
February 23, 2026
Via
The Motley Fool
Topics
Stocks
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
↗
February 22, 2026
Via
The Motley Fool
Topics
Intellectual Property
Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer
February 19, 2026
Via
MarketMinute
A Look Into Novartis Inc's Price Over Earnings
↗
February 17, 2026
Via
Benzinga
Promethos Capital Liquidates $4 Million Sprouts Farmers Market Position: Should Investors Sell, Too?
↗
February 16, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts
↗
February 16, 2026
Via
The Motley Fool
Topics
ETFs
Stocks
Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise
↗
February 13, 2026
Via
Benzinga
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
February 12, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
February 11, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
February 06, 2026
Via
MarketMinute
Topics
Intellectual Property
The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map
February 06, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse
February 06, 2026
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript
↗
February 06, 2026
Via
The Motley Fool
Topics
Earnings
Novartis (NVS) Q3 2024 Earnings Call Transcript
↗
February 05, 2026
Via
The Motley Fool
Topics
Earnings
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead
↗
February 04, 2026
Via
Benzinga
Topics
Intellectual Property
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook
↗
February 03, 2026
Via
The Motley Fool
Topics
Initial Public Offering
Intellectual Property
Stocks
Veteran Biopharma Engineer Ge Yang Attracts Investor Interest with Vision to Redefine Global Pharma Manufacturing
February 03, 2026
Via
AB Newswire
This Vanguard ETF Has Doubled the S&P 500's Returns Since the Start of 2025. Is It a Buy Now?
↗
February 03, 2026
Via
The Motley Fool
Topics
ETFs
Stocks
Peering Into Novartis AG's Recent Short Interest
↗
February 03, 2026
Via
Benzinga
Frequently Asked Questions
Is Novartis AG Common Stock publicly traded?
Yes, Novartis AG Common Stock is publicly traded.
What exchange does Novartis AG Common Stock trade on?
Novartis AG Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novartis AG Common Stock?
The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
What is the current price of Novartis AG Common Stock?
The current price of Novartis AG Common Stock is 169.22
When was Novartis AG Common Stock last traded?
The last trade of Novartis AG Common Stock was at 02/27/26 02:56 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.